<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073811427784</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073811427784</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Secondary Erythromelalgia Successfully Treated With Intravenous Immunoglobulin</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Moody</surname>
<given-names>Shadé</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811427784">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pacheco</surname>
<given-names>Susan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073811427784">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Butler</surname>
<given-names>Ian J.</given-names>
</name>
<degrees>MBBS, FRACP</degrees>
<xref ref-type="aff" rid="aff1-0883073811427784">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Koenig</surname>
<given-names>Mary Kay</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811427784">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073811427784"/>
</contrib>
</contrib-group>
<aff id="aff1-0883073811427784">
<label>1</label>Department of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Medical School at Houston, Houston, TX, USA</aff>
<aff id="aff2-0883073811427784">
<label>2</label>Department of Pediatrics, Division of Allergy and Immunology, The University of Texas Medical School at Houston, Houston, TX, USA</aff>
<author-notes>
<corresp id="corresp1-0883073811427784">Mary Kay Koenig, MD, Department of Pediatrics, Division of Child and Adolescent Neurology, 6431 Fannin MSB 3.153, Houston, TX 77030 Email: <email>Mary.K.Koenig@uth.tmc.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>7</issue>
<fpage>922</fpage>
<lpage>923</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Erythromelalgia is a rare condition characterized by episodic painful erythema and warmth often affecting, but not limited to, the distal extremities. This condition is notoriously difficult to treat. We report a young female patient with seronegative polyarthritis who presented with a 6-year history of recurrent bouts of painful erythema and swelling often triggered by minor trauma. An extensive evaluation was unremarkable. Several medical therapies provided limited and inconsistent relief of her symptoms over many years. Treatment with intravenous immunoglobulin significantly decreased the frequency and severity of her symptoms.</p>
</abstract>
<kwd-group>
<kwd>erythromelalgia</kwd>
<kwd>autoimmune</kwd>
<kwd>intravenous immunoglobulin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Erythromelalgia is characterized by episodic burning sensation, extremity warmth, pain, and erythema often triggered by heat or minor trauma and alleviated by cooling or extremity elevation.<sup>
<xref ref-type="bibr" rid="bibr1-0883073811427784">1</xref>
<xref ref-type="bibr" rid="bibr2-0883073811427784"/>
<xref ref-type="bibr" rid="bibr3-0883073811427784"/>
<xref ref-type="bibr" rid="bibr4-0883073811427784"/>
<xref ref-type="bibr" rid="bibr5-0883073811427784"/>–<xref ref-type="bibr" rid="bibr6-0883073811427784">6</xref>
</sup> The primary form of erythromelalgia is associated with mutations in the sodium channel Nav1.7 encoded by the <italic>SCN9A</italic> gene.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811427784">2</xref>
<xref ref-type="bibr" rid="bibr3-0883073811427784"/>
<xref ref-type="bibr" rid="bibr4-0883073811427784"/>–<xref ref-type="bibr" rid="bibr5-0883073811427784">5</xref>
</sup> Secondary forms are most often associated with myeloproliferative diseases.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811427784">2</xref>
<xref ref-type="bibr" rid="bibr3-0883073811427784"/>
<xref ref-type="bibr" rid="bibr4-0883073811427784"/>
<xref ref-type="bibr" rid="bibr5-0883073811427784"/>
<xref ref-type="bibr" rid="bibr6-0883073811427784"/>–<xref ref-type="bibr" rid="bibr7-0883073811427784">7</xref>
</sup> Both forms are difficult for physicians to treat effectively.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811427784">2</xref>,<xref ref-type="bibr" rid="bibr3-0883073811427784">3</xref>,<xref ref-type="bibr" rid="bibr5-0883073811427784">5</xref>
<xref ref-type="bibr" rid="bibr6-0883073811427784"/>–<xref ref-type="bibr" rid="bibr7-0883073811427784">7</xref>
</sup> The association of secondary erythromelalgia with autoimmune conditions has led to the consideration that autoantibodies directed against the sodium channel encoded for by the <italic>SCN9A</italic> gene may be present in patients with secondary erythromelalgia.<sup>
<xref ref-type="bibr" rid="bibr4-0883073811427784">4</xref>
</sup> Immune-modulating therapy may thus be beneficial in decreasing the severity and frequency of painful and debilitating exacerbations in these patients. We report a young female with secondary erythromelalgia who, after failing a number of other therapies, had a significant reduction in the frequency and severity of her symptoms with intravenous immunoglobulin infusions.</p>
<sec id="section2-0883073811427784">
<title>Case Report</title>
<p>An 18-year-old female with a strong family history of autoimmune diseases and a personal history of seronegative polyarthritis presented with recurrent episodes of painful localized and regional erythema and edema triggered by minor trauma. Episodes began at 12 years of age with numbness and decreased skin temperature followed by painful erythema and edema in the affected body part. She had episodic involvement of contiguous areas of her face and neck with recurrent hordeola and an episode of dysphagia. She also had bouts with single extremity, unilateral upper and lower extremity, or bilateral lower extremity involvement. On initial examination, she was cooperative and in no apparent distress. General physical and neurologic examinations were normal. Examination of the affected extremity showed red-purple discoloration and swelling extending from the left knee to the toes. Pain was present at rest and exacerbated by touch. Skin temperature was normal.</p>
<p>Magnetic resonance imaging of the lumbar spine, hips, and foot was unremarkable as were Doppler vascular studies of the extremities. Complete blood count including platelet count; hemoglobin electrophoresis; flow cytometry; liver function studies; antinuclear antibody; rheumatoid factor; HLA-B27; Sjögren antibodies; thyroid function studies; complement and immunoglobulin levels; erythrocyte sedimentation rate; C reactive protein; rapid plasma reagin; human immunodeficiency virus serology; hepatitis A, B, and C serologies; vitamins E and B<sub>12</sub> levels; and serum and red blood cell folate levels were unremarkable. She was diagnosed with secondary erythromelalgia.</p>
<p>Over the course of her illness, episodes increased in frequency, duration, and severity. Attempts at symptomatic treatment with peripheral nerve blocks, antiepileptic drugs, sodium channel–blocking agents, amitriptyline, duloxetine, pregabalin, steroids, narcotics, nonsteroidal anti-inflammatory agents, and lidocaine patches would provide temporary relief, but were largely unsuccessful at attenuating her episodes. At age 19 years, therapy with intravenous immunoglobulin was initiated. Administration of 2 doses of intravenous immunoglobulin at 1 g/kg per dose 48 hours apart decreased the frequency and severity of her pain episodes from 2-week attacks occurring every 2 months to 2- to 3-day attacks occurring every 6 months. Problems with her insurance prevented prophylactic therapy, and she was given intravenous immunoglobulin only with exacerbations. At age 21 years, she became pregnant. During pregnancy, she had a single minor clinical exacerbation and did not receive intravenous immunoglobulin. Currently, she is 22 years old and she has not had further exacerbations since pregnancy.</p>
</sec>
<sec id="section3-0883073811427784">
<title>Discussion</title>
<p>Erythromelalgia is a rare condition characterized by episodic bouts of burning pain, erythema, warmth, and edema, most commonly involving the extremities, although the face, ears, and neck can be involved.<sup>
<xref ref-type="bibr" rid="bibr1-0883073811427784">1</xref>
<xref ref-type="bibr" rid="bibr2-0883073811427784"/>
<xref ref-type="bibr" rid="bibr3-0883073811427784"/>
<xref ref-type="bibr" rid="bibr4-0883073811427784"/>
<xref ref-type="bibr" rid="bibr5-0883073811427784"/>
<xref ref-type="bibr" rid="bibr6-0883073811427784"/>–<xref ref-type="bibr" rid="bibr7-0883073811427784">7</xref>
</sup> Symptoms are often triggered by minor trauma, exercise, or heat exposure and are often alleviated by cooling and elevation of the involved extremity.<sup>
<xref ref-type="bibr" rid="bibr1-0883073811427784">1</xref>
<xref ref-type="bibr" rid="bibr2-0883073811427784"/>
<xref ref-type="bibr" rid="bibr3-0883073811427784"/>
<xref ref-type="bibr" rid="bibr4-0883073811427784"/>
<xref ref-type="bibr" rid="bibr5-0883073811427784"/>–<xref ref-type="bibr" rid="bibr6-0883073811427784">6</xref>
</sup> Primary erythromelalgia can be familial or sporadic<sup>
<xref ref-type="bibr" rid="bibr1-0883073811427784">1</xref>,<xref ref-type="bibr" rid="bibr3-0883073811427784">3</xref>,<xref ref-type="bibr" rid="bibr4-0883073811427784">4</xref>,<xref ref-type="bibr" rid="bibr6-0883073811427784">6</xref>,<xref ref-type="bibr" rid="bibr7-0883073811427784">7</xref>
</sup> and is associated with gain-of-function mutations in the <italic>SCN9A</italic> gene that encodes for a voltage-dependent sodium channel α-subunit.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811427784">2</xref>
<xref ref-type="bibr" rid="bibr3-0883073811427784"/>
<xref ref-type="bibr" rid="bibr4-0883073811427784"/>–<xref ref-type="bibr" rid="bibr5-0883073811427784">5</xref>
</sup> Secondary erythromelalgia associated with underlying neuropathy, autoimmune disease, myeloproliferative disease, or certain drugs.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811427784">2</xref>
<xref ref-type="bibr" rid="bibr3-0883073811427784"/>
<xref ref-type="bibr" rid="bibr4-0883073811427784"/>
<xref ref-type="bibr" rid="bibr5-0883073811427784"/>
<xref ref-type="bibr" rid="bibr6-0883073811427784"/>–<xref ref-type="bibr" rid="bibr7-0883073811427784">7</xref>
</sup> It has been postulated that patients with secondary erythromelalgia may have activating antibodies to the Nav1.7 channel encoded for by the <italic>SCN9A</italic> gene.<sup>
<xref ref-type="bibr" rid="bibr4-0883073811427784">4</xref>
</sup>
</p>
<p>Erythromelalgia is notoriously difficult to treat.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811427784">2</xref>,<xref ref-type="bibr" rid="bibr3-0883073811427784">3</xref>,<xref ref-type="bibr" rid="bibr5-0883073811427784">5</xref>
<xref ref-type="bibr" rid="bibr6-0883073811427784"/>–<xref ref-type="bibr" rid="bibr7-0883073811427784">7</xref>
</sup> Many drugs such as antiepileptics, narcotics, tricyclic antidepressants, serotonin reuptake inhibitors, vasodilating medications, γ-aminobutyric acid agonists, and drugs that act on sodium channels have been tried with limited and inconsistent benefit.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811427784">2</xref>
<xref ref-type="bibr" rid="bibr3-0883073811427784"/>
<xref ref-type="bibr" rid="bibr4-0883073811427784"/>
<xref ref-type="bibr" rid="bibr5-0883073811427784"/>–<xref ref-type="bibr" rid="bibr6-0883073811427784">6</xref>
</sup> Surgical procedures such as nerve blocks and sympathectomy have also shown limited benefit.<sup>
<xref ref-type="bibr" rid="bibr6-0883073811427784">6</xref>
</sup> Our patient received a number of therapies but did not have consistent or sustained relief until she received intravenous immunoglobulin infusions. Jackson et al similarly reported improvement in the symptoms of erythromelalgia with intravenous immunoglobulin infusions in a patient with secondary erythromelalgia.<sup>
<xref ref-type="bibr" rid="bibr4-0883073811427784">4</xref>
</sup> Since there is evidence of underlying autoimmune abnormalities in the majority of patients with secondary erythromelalgia, intravenous immunoglobulin should be considered first-line therapy for these patients. As demonstrated by our patient, this therapy can decrease the frequency and severity of attacks in this debilitating condition.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-0883073811427784">
<label>Author Contributions</label>
<p>SM contributed to data collection and the first draft of the manuscript. SP, IB, and MKK participated in critical evaluation and revisions of the manuscript.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073811427784">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073811427784">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="other" id="fn4-0883073811427784">
<label>Ethical Approval</label>
<p>The writing/research of this article did not require ethical approval.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073811427784">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalgaard</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Clausen</surname>
<given-names>OP</given-names>
</name>
<name>
<surname>Mellbye</surname>
<given-names>OJ</given-names>
</name>
<name>
<surname>Hovig</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kvernebo</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Nonspecific capillary proliferation and vasculopathy indicate skin hypoxia in erythromelalgia</article-title>. <source>Arch Dermatol</source>. <year>2011</year>;<volume>147</volume>(<issue>3</issue>):<fpage>309</fpage>–<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr2-0883073811427784">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latessa</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title> Erythromelalgia: A rare microvascular disease</article-title>. <source>J Vasc Nurs</source>. <year>2010</year>;<volume>28</volume>:<fpage>67</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr3-0883073811427784">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaur</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koroscil</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Late-onset erythromelalgia in a previously healthy young woman: A case report and review of literature</article-title>. <source>J Med Case Reports</source>. <year>2009</year>;<volume>3</volume>:<fpage>106</fpage>.</citation>
</ref>
<ref id="bibr4-0883073811427784">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oates</surname>
<given-names>J. A</given-names>
</name>
</person-group> <article-title>patient with adult erythermalgia: Evidence suggesting an autoimmune etiology</article-title>. <source>Am J Med Sci</source>. <year>2008</year>;<volume>335</volume>(<issue>4</issue>):<fpage>320</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr5-0883073811427784">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badeloe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Henquet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nieuwhof</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Secondary erythromelalgia involving the ears probably preceding lupus erythematosus</article-title>. <source>Int J Dermatol</source>. <year>2007</year>;<volume>46</volume>(<issue>suppl. 3</issue>):<fpage>6</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr6-0883073811427784">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rooke</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Erythromelalgia</article-title>. <source>Curr Treat Options Cardiovasc Med</source>. <year>2006</year>;<volume>8</volume>:<fpage>153</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr7-0883073811427784">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Layzer</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Hot feet: Erythromelalgia and related disorders</article-title>. <source>J Child Neurol</source>. <year>2001</year>;<volume>16</volume>:<fpage>199</fpage>–<lpage>202</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>